Your browser doesn't support javascript.
loading
A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease.
Gonzalez-Ortiz, Fernando; Ferreira, Pamela C L; González-Escalante, Armand; Montoliu-Gaya, Laia; Ortiz-Romero, Paula; Kac, Przemyslaw R; Turton, Michael; Kvartsberg, Hlin; Ashton, Nicholas J; Zetterberg, Henrik; Harrison, Peter; Bellaver, Bruna; Povala, Guilherme; Villemagne, Victor L; Pascoal, Tharick A; Ganguli, Mary; Cohen, Anne D; Minguillon, Carolina; Contador, Jose; Suárez-Calvet, Marc; Karikari, Thomas K; Blennow, Kaj.
Affiliation
  • Gonzalez-Ortiz F; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Ferreira PCL; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • González-Escalante A; Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Montoliu-Gaya L; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Ortiz-Romero P; Hospital del Mar Research Institute, Barcelona, Spain.
  • Kac PR; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Turton M; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Kvartsberg H; Hospital del Mar Research Institute, Barcelona, Spain.
  • Ashton NJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Zetterberg H; Bioventix Plc, 7 Romans Business Park, Farnham, Surrey, UK.
  • Harrison P; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Bellaver B; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Povala G; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Villemagne VL; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Pascoal TA; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
  • Ganguli M; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.
  • Cohen AD; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Minguillon C; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Contador J; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
  • Suárez-Calvet M; UK Dementia Research Institute at UCL, London, UK.
  • Karikari TK; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
  • Blennow K; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alzheimers Dement ; 20(2): 1239-1249, 2024 Feb.
Article in En | MEDLINE | ID: mdl-37975513
INTRODUCTION: Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited. METHODS: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaßeta Brain Research Center's Alzheimer's At-Risk Cohort [ß-AARC]). RESULTS: UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80-0.91) identifying amyloid beta (Aß) pathology, determined either by Aß positron emission tomography or CSF Aß42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aß42/40 ratio (AUC = 0.91). DISCUSSION: UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction Limits: Humans Language: En Journal: Alzheimers Dement Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction Limits: Humans Language: En Journal: Alzheimers Dement Year: 2024 Document type: Article Affiliation country: Country of publication: